Navigation Links
Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
Date:9/23/2011

result in overdose and death.Summary of Clinical StudyPatients evaluated in this randomized, double-blind, double-dummy active controlled, superiority study had moderate-to-severe low back pain for at least three months and were receiving treatment with opioid analgesics at doses between 30 to 80 mg of morphine sulfate or the equivalent at least four days per week for at least 30 days prior to the screening visit.  Sixty-two percent (62%) of patients were taking hydrocodone-containing medications; 21% were taking oxycodone-containing medications; and 12% of patients were taking propoxyphene-containing medications.  Prospective patients were excluded if they were currently using the fentanyl transdermal-system, extended-release hydromorphone, or more than 80 mg per day of oral morphine equivalent for pain control upon entry into the study.

The study employed an enriched design – allowing only patients who both tolerated and responded to Butrans during an open label run-in period to enter into the 12-week double-blind phase of the trial, mimicking the treatment of patients in a clinical practice setting.  

The efficacy and safety of Butrans 20 mcg/hour was assessed using Butrans 5 mcg/hour as the low-dose control group.  All patients wore either active or placebo patches (double-dummy technique).  The study was performed at 75 centers in the United States.

Of the 1160 patients that entered the open-label run-in period, 57% were able to titrate to and tolerate the adverse effects of Butrans 20 mcg/hour and were randomized into a 12-week double-blind treatment phase.  Twelve percent (12%) of patients discontinued due to an adverse event and 21% discontinued due to lack of a therapeutic effect during the open-label titration period. A total of 660 patients were randomized to the double-blind phase to receive Butrans 20 mcg/hour, Butrans 5 mcg/hour, or an active control, for 12 weeks.  During the double-blind t
'/>"/>

SOURCE Purdue Pharma L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AIMs Program for Improving Echocardiography Appropriateness Yields Impressive Results
2. Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results
3. Accuray Announces Results for Fourth Quarter and Fiscal Year 2011
4. Misonix Schedules Fourth Quarter and Year-End Fiscal 2011 Financial Results Conference Call; September 20, 2011 at 4:30 p.m. Eastern
5. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
6. Pro-Dex, Inc. Announces Fiscal 2011 Fourth Quarter and Full-Year Results
7. Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon
8. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2012 Results
9. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
10. Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraColl® for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
11. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- Reportlinker.com announces that a new market research ... Global Patient Scales Industry ... worldwide markets for Patient Scales in US$ Thousand ... & Baby Scales, Chair Scales, and Under Bed ... the US, Canada, Japan, Europe, Asia-Pacific, Latin America, ...
(Date:8/20/2014)... Phase I Trial of Plasma ... KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a ... it has begun a Phase I, First in Human, ... the treatment of DME. The study,s Principal Investigator is ... Joslin Diabetes Center; Harvard Medical School Department of Ophthalmology, ...
(Date:8/19/2014)... , Aug. 19, 2014  Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... announced last Thursday, August 14, 2014, has closed.  The ... convertible at $7.30 per share of common stock.  The ... to purchase up to an additional 30% of these ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3
(Date:8/20/2014)... 20, 2014 In its latest blog post, ... treatment program that gets clients off to a great start ... believe in, is highlighting an important and possibly life-changing – ... everyone who wants to understand the insidious nature of drug ... belief that drug abuse targets a certain socioeconomic group, such ...
(Date:8/20/2014)... Texas Medical Research Associates is looking for ... help test the effectiveness of a new drug looking to ... be eligible to participate in the study. , According to ... can lead to cardiovascular disease, the no. 1 cause of ... the risk of heart disease and stroke. People with high ...
(Date:8/20/2014)... sleep may wake up to worse consequences than nodding ... of being obese by age 21 was 20 percent ... of sleep a night, compared with their peers who ... Control and Prevention recommends nine to ten hours of ... of Public Health at Columbia University and the University ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 According to ... on August 7 in the multicounty litigation (MCL) case ... RE DEPUY ASR HIP IMPLANTS LITIGATION; no. BER-L-3971-11), nearly ... have been dismissed without prejudice. The cases enumerated in ... of being resolved.” The Rottenstein Law Group LLP, a ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) ... AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the ... to grow to $15.2 billion by 2019, with ... 15.9%. Increasing industrialization is driving significant growth ... expanding range of industrial applications such as military ...
Breaking Medicine News(10 mins):Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3Health News:Texas Medical Research Associates Announce New Study 2Health News:Teen sleeplessness piles on risk for obesity 2Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3
... The American Journal of Gastroenterology suggests that smoking may ... in those// who suffer from Crohn’s disease. Where the ... eventually require surgical treatment. ,“In patients who ... the small intestine, rather than the colon,” says study ...
... cold may cause uncommon ailments if neglected, specialists warn. // ... have always thought it is harmless. But specialists say it ... also negatively impact vision or cause harm to any part ... cases of chronic sinusitis because of unchecked pollution. Chronic sinus ...
... has been recommended for medical conditions such as endometriosis, ... choice for women who dislike menstruation or find it ... and is it a reasonable lifestyle choice, asks Paula ... ,Birth control options that reduce or eliminate periods ...
... new cancer research study that may be the ‘last best ... to discover the genetic and environmental factors that cause and ... aims to enroll a geographically and ethnically diverse group of ... pave the way for the next generation of American Cancer ...
... the counter (OTC) drugs can be highly addictive, warn two ... of dependency on OTC drugs is often forgotten, write Drs ... months, they describe seeing three patients with addictions to Nurofen ... started using the product for its approved indications, but their ...
... benefit from having a tonsillectomy in the short term, ... and any benefits have to be balanced against the ... small study of adults from Finland showed that tonsillectomy ... days, compared with watchful waiting. ,But despite ...
Cached Medicine News:Health News:A Cold Shoulder to Cold - At Your Risk 2Health News:Should Menstrual Suppression Be a Lifestyle Choice? 2Health News:American Cancer Society Launches Major New Study 2Health News:American Cancer Society Launches Major New Study 3Health News:Is It Worth Having Surgery to Remove Your Tonsils? 2
... contamination, which causes false ... Hydrophobic, nonwicking and self-sealing ... pass through these aerosol-resistant ... to tips with absorption ...
Inquire...
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Medicine Products: